Cullinan Therapeutics

In my years treating people with acute myeloid leukemia (AML), I witnessed far too many patients exhaust their options, facing relapse with nowhere left to turn. While immunotherapies have transformed progress across other blood cancers, AML has remained stubbornly out of reach. That needs to change. At Cullinan Therapeutics, we’re seeing early signs that it can. Compelling data shared during #ASH25 indicates our investigational T cell engager, CLN-049, could harness the immune system against AML and offer a potent, flexible, and differentiated therapeutic strategy for a broad population. While there’s still much work ahead, these promising early signals motivate our efforts to advance science with purpose and finally reach patients who need new treatment options.

Acute myeloid leukemia is a devastating blood cancer with no approved immunotherapies, often leaving patients with limited options and poor outcomes. We’re evaluating CLN-049, our investigational FLT3xCD3 T cell engager, and its potential to be widely applicable to a broad population in AML.

We’re leveraging our team’s deep understanding of the immune system and extensive experience in oncology as we explore the potential of T cell engagers to deliver new standards of care for those living with cancers like acute myeloid leukemia. Discover our unique approach to accelerating the development of high-impact therapies for patients in need.

Despite recent advances, there are many people living with blood cancer in need of new treatment options that could make a meaningful difference. In acute myeloid leukemia (AML), we are evaluating the potential of CLN-049, our investigational FLT3xCD3 T cell engager, to harness the immune system and redirect T cells to recognize and eliminate cancerous cells. Learn more about the promise of CLN-049 as we aim to redefine the treatment landscape for those living with relapsed/refractory AML.

Here at Cullinan, the best science doesn’t just move forward – it moves people. We accelerate high-impact solutions across autoimmune diseases and cancer, innovating with intent, with the goal of delivering new standards of care for patients. Discover how we are setting this scientific approach in motion: https://lnkd.in/e9Ji7wiQ #ScienceThatMoves